Clinical Evidence: What UK Weight Loss Trials Actually Show
Mounjaro vs Wegovy UK: Understanding the Clinical Evidence Base
When comparing Mounjaro vs Wegovy UK weight loss results, it's essential to examine the robust clinical trial data that supports both treatments. The STEP programme for Wegovy demonstrates compelling evidence, with STEP 1 showing approximately 15% average weight loss at 68 weeks when patients took Wegovy alongside diet and exercise modifications. STEP 3 achieved even higher results at ~16% with intensive behavioural therapy support, whilst STEP 5 demonstrated sustained results of ~15.2% at the two-year mark. These prescription-only medicines work through different mechanisms, with Wegovy targeting GLP-1 receptors specifically.
Mounjaro's clinical programme shows its own distinct profile as a dual GIP and GLP-1 receptor agonist, though direct head-to-head comparisons aren't available due to different trial designs and patient populations. Both treatments require clinical assessment and prescriber oversight, ensuring you receive appropriate monitoring throughout your weight management journey. The key difference lies in their mechanisms: Wegovy works purely through GLP-1 pathways, while Mounjaro engages both GIP and GLP-1 systems for appetite regulation and metabolic support.
UK Pricing Analysis: Mounjaro vs Wegovy Cost Comparison
Understanding the cost implications when comparing Mounjaro vs Wegovy UK options requires transparent pricing information. Wegovy follows a structured dose escalation: 0.25mg starter pens cost £79.99, progressing to 0.5mg at £94.99, then 1mg at £99.99, 1.7mg at £139.99, and maintenance 2.4mg at £209.99. Our Getting Started bundles provide convenience, such as the Intro Duo (0.25mg & 0.5mg) for £169.99, eliminating the need for multiple orders during your initial months. New customers apply code FIRST40 at checkout, whilst returning customers use DOSE25 to access these competitive prices.
Bundle options like our Progress Trio (0.5mg, 1mg & 1.7mg) at £369.99 ensure continuous supply without interruption. Mounjaro pricing varies due to its different dosing schedule and titration pattern. Both medications require the same rigorous clinical assessment process through our GPhC-registered pharmacy (#9012878), ensuring proper medical oversight regardless of your choice. The convenience factor of our bundled pricing eliminates supply gaps that could disrupt your weight management progress.
STEP Trial Results: Evidence-Based Wegovy Outcomes in Clinical Studies
The STEP clinical programme provides the foundation for understanding Wegovy's weight loss potential in controlled settings. STEP 1, published by Wilding et al. in NEJM 2021, demonstrated that patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks compared to 2.4% with placebo. STEP 2 specifically examined patients with type 2 diabetes, showing ~9.6% weight reduction, whilst STEP 3 combined Wegovy with intensive behavioural therapy for ~16% results.
The SELECT trial added cardiovascular benefits to the equation, demonstrating a 20% reduction in major cardiovascular events (HR 0.80) alongside weight management outcomes. STEP 5's two-year data confirmed sustained results at ~15.2%, though the extension study showed patients regained approximately two-thirds of weight lost within one year of stopping treatment. This underscores that weight management represents a long-term commitment rather than a short-term intervention.
How Wegovy Works: GLP-1 Mechanism for UK Weight Management
Wegovy functions as a GLP-1 receptor agonist, mimicking your body's natural fullness hormone to regulate appetite and food intake. When you inject Wegovy once weekly, it activates GLP-1 receptors in your brain's appetite centres, reducing hunger signals and promoting satiety after smaller meals. The medication may also slow gastric emptying, helping you feel satisfied for longer periods after eating. This mechanism works alongside your reduced-calorie diet and increased physical activity to support sustainable weight management. Clinical studies suggest Wegovy may reduce food cravings, particularly for high-calorie foods, though individual responses vary. The once-weekly FlexTouch pen delivery system maintains consistent medication levels throughout the week, supporting steady appetite regulation.
UK Ordering Process: From Assessment to Delivery for Wegovy
Accessing Wegovy through EverydayMeds begins with our comprehensive 3-minute online clinical assessment, covering your medical history, current medications, and weight management goals. Our UK-registered prescribers review your application within three working days (or 24 hours with express service), ensuring appropriate clinical oversight before prescribing this prescription-only medicine. Once approved, your Wegovy ships via next-day delivery using cold-chain temperature-controlled packaging to maintain medication integrity. We provide detailed injection instructions, dose escalation schedules, and ongoing support throughout your treatment journey. The entire process maintains MHRA compliance and GPhC standards, ensuring you receive genuine Novo Nordisk Wegovy with proper pharmaceutical oversight.
Storage Advantages: Wegovy vs Mounjaro UK Practical Considerations
Storage requirements present a practical advantage when comparing Mounjaro vs Wegovy UK options for active lifestyles. Wegovy tolerates room temperature storage below 30°C for up to six weeks once removed from refrigeration, compared to Mounjaro's 21-day room temperature limit. This flexibility proves valuable for UK travel, work schedules, or situations where refrigeration isn't consistently available. Before first use, store Wegovy in your fridge at 2-8°C, transitioning to the FlexTouch pen's user-friendly injection system. The dose escalation protocol requires strict adherence: you cannot skip doses or accelerate the titration schedule from 0.25mg through to 2.4mg maintenance. Each pen contains four doses, lasting one month at the prescribed weekly injection schedule.
UK Regulatory Status: MHRA Approval and NICE Guidance for Both Treatments
Both Mounjaro and Wegovy hold MHRA licensing for weight management in UK adults with BMI ≥30, or BMI ≥27 with weight-related comorbidities. NICE TA875 specifically recommends Wegovy alongside specialist weight management support, establishing its place in UK clinical practice. The MHRA's Black Triangle (▼) designation indicates additional monitoring for both treatments, reflecting their relatively recent introduction to the UK market. Wegovy also received approval for adolescents aged 12 years and above with body weight over 60kg and BMI corresponding to ≥30 in adults.
The 6th January 2026 MHRA approval of Wegovy 7.2mg represents the latest development, though this higher dose isn't yet available through EverydayMeds. Both medications require prescription alongside reduced-calorie diet and increased physical activity, emphasising the holistic approach to weight management. Our GPhC-registered pharmacy ensures compliance with all UK regulatory requirements for prescription-only medicine supply and patient safety monitoring.
Making Your Choice: Clinical Support for Mounjaro vs Wegovy UK Decisions
Both Wegovy and Mounjaro are available from EverydayMeds, and your prescriber can help determine which treatment aligns with your specific clinical profile and weight management goals. The decision involves considering factors like your medical history, previous weight loss attempts, lifestyle requirements, and individual response patterns. Our clinical team evaluates each application individually, ensuring appropriate treatment selection based on current UK guidelines and your personal circumstances. Rather than declaring one treatment superior, we focus on matching you with the most suitable option for your situation, whether that's Wegovy's established GLP-1 mechanism or Mounjaro's dual-agonist approach. Ready to begin your clinically-supported weight management journey? Complete our 3-minute assessment today, apply code FIRST40 for new customers, and take the first step toward evidence-based weight management with confidence.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
